Skip to main content

We’re not only bridging the barrier between mind and body, but we’re also making headlines with our innovative digital therapeutics.

PRESS RELEASES AND ANNOUNCEMENTS

metaMe Health Receives FDA Clearance for Regulora®, the First FDA-authorized Treatment Specifically for Abdominal Pain Due to Irritable Bowel Syndrome (IBS)

Abdominal pain is the primary symptom of all IBS subtypes (IBS-C, IBS-D, and IBS-M), and is the number one reason patients seek treatment for their IBS. Regulora®Read more

metaMe Health Announces First Subject Enrolled in Pivotal Study of a Digital Therapeutic for Treatment of IBS

CHICAGO (October 31, 2019) — metaMe Health, Inc., a Chicago-based prescription digital therapeutics company committed to the treatment of gastrointestinal… Read more

metaMe Health Secures $3.8 Million in Seed Funding

metaMe Health, a Chicago-based prescription digital therapeutics company committed to the treatment of gastrointestinal (GI) conditions such as Irritable… Read more


COMPANY AND INDUSTRY NEWS

In just a few short years, digital therapeutics (DTx) have become an exciting, incredibly competitive new frontier in healthcare. For those not familiar… Read more

Digital therapeutics (DTx)—software that delivers a clinical mechanism of action, either alone or in combination with other standard-of-care treatments… Read more

Chicago Bootcamps featured metaMe Health in their list of the 60 Chicago Startups to Watch in 2020. The list highlights the most promising companies… Read more

STAY CONNECTED TO THE FUTURE OF
PRESCRIPTION DIGITAL THERAPIES

Join our mailing list. Or to become an investor, contact us directly.

    .